drugset

drugset / Trial / NCT00838890

A Study of BMS-863233 in Patients With Hematologic Cancer

NCT00838890 ↗

Phase 1/2 Terminated 11 enrolled Bristol-Myers Squibb Exelixis · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer

Timeline

Start: 2009-03
Primary completion: 2010-01
Completion: 2010-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	BMS-863233	Small molecule	—	Oral

Indications